Oncolytics Biotech® and SOLTI announce upcoming poster presentation at the meeting of the European Society of Medical Oncology on Breast Cancer

Oncolytics Biotech® and SOLTI announce upcoming poster presentation at the meeting of the European Society of Medical Oncology on Breast Cancer

SAN DIEGO, California And CALGARY, AB, May 2, 2022 / PRNewswire / – Oncolytic Biotechnology® Inc. (NASDAQ: ONCY) (TSX: ONC) and SOLTI-Innovative Cancer Research today announced the acceptance of an abstract for the presentation of a poster at the upcoming meeting of the European Society of Medical Oncology on Breast Cancer, to be held both online and in person at hub27 – Messe Berlin a Berlin, Germany from May 3-5, 2022.

The accepted abstract (# 364) is available on the ESMO Breast Cancer Meeting website. The abstract includes new results from cohort 1 and cohort 2 from the AWARE-1 ​​study, a collaboration between Oncolytics Biotech and SOLTI, each enrolling ten patients with early stage HR + / HER2- breast cancer. These patients were treated with pelareorep and the aromatase inhibitor letrozole without (cohort 1) or with (cohort 2) the PD-L1 checkpoint inhibitor atezolizumab. Evaluation of these cohorts was the primary focus of AWARE-1 ​​as HR + / HER2- is the breast cancer subtype that Oncolytics intends to investigate in a future registration study.

The results of this exploratory study described in the abstract show the potential of pelareorep to induce an inflamed tumor phenotype and its synergy with atezolizumab. They also support pelareorep’s immune-based mechanism of action and suggest that the combination of pelareorep and atezolizumab may improve outcomes in breast cancer. Further details on the analyzes and results described in the abstract will be provided after the publication of the corresponding poster, in accordance with the embargo policies of the ESMO Breast Cancer Meeting.

Below are details on the abstract and the upcoming poster presentation.

Title: Pelareorep Oncolytic Virus Prepares Tumor Microenvironment for Checkpoint Blockage Therapy in Early Breast Cancer Patients – AWARE-1 ​​Study Results

Category: Biomarkers and translational research and precision medicine

Abstract number: 364

Submission date: May 4, 2022

Presentation time: 12:15 CET

About AWARE-1

AWARE-1 ​​was an open-label, window-of-opportunity study in early stage breast cancer. The study combined pelareorep, without or with atezolizumab, and standard therapy based on breast cancer subtype. Tumor tissue was collected from the patients as part of their initial breast cancer diagnosis, always on the third day after initial treatment and finally three weeks after treatment, the day the tumor is surgically removed. The key objectives of the study were to confirm that pelareorep acts as a new immunotherapy, to evaluate the potential synergy between pelareorep and checkpoint blockade, and to collect biomarker data. The primary endpoint of the translational study was the overall CelTIL score (a measure of cellularity and tumor-infiltrating lymphocytes). Secondary endpoints of the study included safety and tumor and blood-based biomarkers.

About Oncolytics Biotech Inc.

Oncolytics is a biotechnology company that develops pelareorep, an intravenously administered immunotherapy agent. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype – turning “cold” tumors into “hot” tumors – through innate and adaptive immune responses to treat a variety of cancers.

Pelareorep has shown synergies with immune checkpoint inhibitors and may also be synergistic with other approved cancer treatments. Oncolytics is currently conducting and planning clinical trials to evaluate pelareorep in combination with checkpoint inhibitors and targeted therapies in solid and hematologic malignancies as it progresses towards a registration study in metastatic breast cancer. For more information, please visit: www.oncolyticsbiotech.com.

This press release contains forward-looking statements, pursuant to Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as “forward-looking statements”). Forward-looking statements contained in this press release include statements regarding Oncolytics’ belief in the potential and benefits of pelareorep as a cancer therapy; the timing and expected content of the presentation of the poster at the next meeting of the European Society of Medical Oncology on Breast Cancer; our plans to move towards a registration study in metastatic breast cancer; and other statements regarding anticipated developments in Oncolytics’ business and technologies. In any forward-looking statement where Oncolytics expresses an expectation or belief about future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there is no guarantee that the statement or expectation or belief will be reached up. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, inter alia, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical trials and trials, the ability to Oncolytics to successfully commercialize pelareorep, uncertainties related to research and development of pharmaceutical products, uncertainties related to the regulatory process and general changes in the economic environment. In particular, we may be affected by business disruptions due to the COVID-19 coronavirus, including delays and disruptions in operations, production supply chain, clinical trials and project development, labor shortages, disruptions to travel and shipping and arrests (including due to government regulatory and preventive measures). It is not known whether and how oncolytics can be affected if the COVID-19 pandemic persists for an extended period of time. We may incur expenses or delays relating to such events beyond our control, which could have a material adverse impact on our business, operating results and financial condition. Investors should consult Oncolytics’ quarterly and annual documents at the Canadian and US securities committees for more information on the risks and uncertainties surrounding forward-looking statements. Investors are cautioned not to place undue reliance on forward-looking statements. The Company undertakes no obligation to update these forward-looking statements, except as required by applicable law.

Company contact

Jon Patton

Director of IR and communication

+ 1-858-886-7813

[email protected]

Investor Relations for Oncolitics

Timothy McCarthy

LifeSci Consultants

+1917-679-9282

[email protected]

Logo – https://mma.prnewswire.com/media/1808285/Oncolytics_Biotech_Grey.jpg

SOURCE Oncolytics Biotech® Inc.

.

Leave a Comment

Your email address will not be published.